Clinical Trials
Multiple clinical trials are evaluating therapeutic interventions across musculoskeletal, urological, neurodegenerative, and dermatological conditions, including thumb carpometacarpal joint arthritis, medial lobe prostatic hyperplasia, mild cognitive decline associated with Alzheimer's disease, and chronic diabetic foot ulcers. Encompassing Phase 1, Phase 2, and phase-not-applicable studies, recruitment statuses range from not yet recruiting to recruiting. Sponsoring organizations include academic institutions and clinical research groups such as the University of Virginia, Seoul National University Hospital, Helse Stavanger HF with the University of Exeter, and NOxy Health Products LLC with SerenaGroup Inc.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06359665 | Not yet recruiting | Arthritis of Carpometacarpal Joint of Left Thumb|Arthritis of Carpometacarpal Joint of Right Thumb |
Brent DeGeorge|University of Virginia |
2024-06-01 | Phase 1 |
| NCT06177821 | Recruiting | Prostatic Hyperplasia of the Medial Lobe |
Seoul National University Hospital |
2024-06-03 | Not Applicable |
| NCT06362707 | Not yet recruiting | Cognitive Decline Mild|Alzheimer Disease |
Helse Stavanger HF|University of Exeter |
2024-05-01 | Phase 2 |
| NCT06402565 | Not yet recruiting | Diabetic Foot Ulcer |
NOxy Health Products LLC|SerenaGroup Inc. |
2024-05-15 | Phase 1 |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Jump to
- Calcium gluconate monohydrate Solubility in DMSO
- Calcium gluconate monohydrate Stock Solution
- Calcium gluconate monohydrate Storage
- Calcium gluconate monohydrate Stability
- Calcium gluconate monohydrate Molecular Weight
- Calcium gluconate monohydrate SMILES
- Calcium gluconate monohydrate CAS Number
- Calcium gluconate monohydrate Chemical Structure (2D and 3D)
- Calcium gluconate monohydrate SDS|MSDS